HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer

ConclusionOur data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT.

Source: Breast Cancer Research and Treatment - October 31, 2021 Category: Cancer & Oncology Source Type: research